Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Artiva Biotherapeutics logo
$10.72
+0.58 (+5.72%)
(As of 11/1/2024 ET)

About Artiva Biotherapeutics Stock (NASDAQ:ARTV)

Key Stats

Today's Range
$10.04
$10.72
50-Day Range
$9.80
$15.83
52-Week Range
$9.68
$17.31
Volume
31,213 shs
Average Volume
149,088 shs
Market Capitalization
$260.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.25
Consensus Rating
Buy

Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Receive ARTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTV Stock News Headlines

This is treason
If you missed it, my emergency election broadcast is now available - but will be removed soon
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Wedbush
See More Headlines

ARTV Stock Analysis - Frequently Asked Questions

Artiva Biotherapeutics' stock was trading at $11.77 at the beginning of the year. Since then, ARTV stock has decreased by 8.9% and is now trading at $10.72.
View the best growth stocks for 2024 here
.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) released its quarterly earnings data on Thursday, August, 29th. The company reported ($19.10) EPS for the quarter, missing the consensus estimate of ($1.07) by $18.03.

Artiva Biotherapeutics (ARTV) raised $167 million in an initial public offering (IPO) on Friday, July 19th 2024. The company issued 13,920,000 shares at a price of $12.00 per share.

Artiva Biotherapeutics' lock-up period expires on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its initial public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

Last Earnings
8/29/2024
Today
11/02/2024
Next Earnings (Estimated)
12/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ARTV
Previous Symbol
NASDAQ:ARTV
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.25
High Stock Price Target
$23.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+98.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$260.39 million
Optionable
N/A
Beta
N/A
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:ARTV) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners